Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RGN-259 (Thymosin beta 4) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Thymosin Beta-4
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
RGN-259 (Thymosin beta 4) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Thymosin Beta-4
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: HLB Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: HLB Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
RGN-259 (timbetasin acetate) is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK), a persistent corneal defect caused by diabetes and herpes zoster virus, among other pathologies.
Lead Product(s): Timbetasin Acetate,Undisclosed
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
GT90001 is a fully human monoclonal antibody Activin Receptor-Like Kinase-1, Activin Receptor-Like Kinase-1, inhibits ALK-1/TGF-β signal transduction and tumor angiogenesis.
Lead Product(s): GT90001,Nivolumab
Therapeutic Area: Oncology Product Name: PF-03446962
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
The purpose of a pre-BLA meeting is to discuss with FDA the format, content, and acceptability of RGN-259, a sterile, preservative-free eye drop that has been shown to reduce symptoms of dry eye syndrome based on the results to date.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: ReGenTree
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2021
Details:
RGN-259 or Thymosin Beta 4 is timbetasin, a small peptide with G actin-sequestering action. It is associated with induction of angiogenesis, accelerated wound healing and increased metastatic potential of tumor cells.
Lead Product(s): Timbetasin Acetate
Therapeutic Area: Ophthalmology Product Name: RGN-259
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2021